Tag Archive for: Novo Holdings

Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food

/in

COPENHAGEN, DENMARK – Today, Novo Holdings announced an initial investment in Danish food-tech start-up MATR Foods (‘MATR’) to support the scaling-up of its production of sustainable meat alternatives. Established in Copenhagen in 2021, MATR specialises in developing organic innovative plant-based meat alternatives using traditional fungal fermentation techniques. Locally sourced organic ingredients like oats, split peas, […]

Read more

Novo Holdings and DLG Group join forces to advance sustainable crop production

/in

Novo Holdings and DLG Group today announced a strategic partnership to advance sustainable agriculture and food systems. The initial phase includes Novo Holdings acquiring 25% of the shares in Sejet Plant Breeding (Sejet), a leader in agricultural innovation owned by DLG Group. Since 1947, Sejet has been a leading contributor to agricultural innovation, developing and delivering […]

Read more

Novo Holdings announces investment in AgNext Technologies, an agricultural and food technology company developing AI-based solutions for more sustainable agriculture

/in

Copenhagen and Singapore, 25 June 2024 – Novo Holdings today announced that it has led an investment in AgNext Technologies Private Limited, a breakthrough agricultural and food technology company enhancing trust along the food chains by innovating artificial intelligence-based food quality assessment technologies. Founded in 2016 with operations in India and Abu Dhabi, UAE, AgNext Technologies […]

Read more

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

/in

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]

Read more

Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal

/in

Investment firm’s connection to the Novo Nordisk Foundation provides a strong sense of purpose, report employees Award highlights collaborative, respectful workplace, and comprehensive employee benefits Boston, US, 23 May 2024 – Novo Holdings, a leading life science investor, today announced that its Boston office has been named a 2024 Best Place to Work by the Boston Business […]

Read more